论文部分内容阅读
目的探讨吡拉西坦和甘露醇治疗颅内肿瘤术后颅内压增高的疗效及安全性。方法应用随机数字表法将2009年12月至2011年12月在天津市第五中心医院神经外科住院治疗的102例颅内肿瘤术后颅内压增高患者分为对照组(51例)和观察组(51例),对照组患者给予20%甘露醇进行治疗,观察组患者给予吡拉西坦注射液进行治疗,其他治疗措施相同,比较对照组与观察组患者临床疗效和不良反应发生情况。结果观察组患者的治疗总有效率(96.1%)明显高于对照组(84.3%),且对照组与观察组患者在不良反应发生率方面差异无统计学意义(P>0.05)。结论吡拉西坦注射液治疗颅内肿瘤术后颅内压增高疗效确切,能够代替甘露醇用于颅内肿瘤术后颅内压增高患者降颅压治疗,明显提高临床疗效,且不良反应少,值得进一步推广。
Objective To investigate the efficacy and safety of piracetam and mannitol in the treatment of intracranial hypertension after intracranial tumor. Methods A total of 102 patients with intracranial hypertension after intracranial tumor hospitalized in Department of Neurosurgery, the Fifth Central Hospital of Tianjin from December 2009 to December 2011 were randomly divided into control group (n = 51) and observation group (N = 51). Patients in the control group were treated with 20% mannitol. The patients in the observation group were treated with piracetam injection. The other treatment measures were the same. The clinical efficacy and adverse reactions in the control group and the observation group were compared. Results The total effective rate (96.1%) in the observation group was significantly higher than that in the control group (84.3%). There was no significant difference in the incidence of adverse reactions between the control group and the observation group (P> 0.05). Conclusion Piracetam injection for intracranial tumors after intracranial hypertension increased curative effect, can replace mannitol for intracranial tumor intracranial pressure intracranial pressure after intracranial pressure treatment, significantly improve the clinical efficacy, and fewer adverse reactions , Worth further promotion.